stockrowIovance Biotherapeutics, Inc.
IOVA Healthcare Biotechnology
Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.
- Revenue
- +80.1%
- EPS
- +80.0%
- Free cash flow
- +89.7%
Quarter to September 2026, against a year earlier
Follow IOVA
Alert me
Iovance Biotherapeutics, Inc. (IOVA) Net income
Iovance Biotherapeutics, Inc.'s net income for fiscal 2025 was −$391.0M, compared with −$372.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$220.5M. Over the past ten years it has ranged from −$444.0M (fiscal 2023) to −$27.7M (fiscal 2015); the current reading is higher than 27% of that period. Iovance Biotherapeutics, Inc. ranks 533rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$391.0M | — |
| FY2024 | −$372.2M | — |
| FY2023 | −$444.0M | — |
| FY2022 | −$395.9M | — |
| FY2021 | −$342.3M | — |
| FY2020 | −$259.6M | — |
| FY2019 | −$197.6M | — |
| FY2018 | −$123.6M | — |
| FY2017 | −$92.1M | — |
| FY2016 | −$52.9M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$22.3M | — |
| Jun 2026 | −$47.3M | — |
| Mar 2026 | −$79.0M | — |
| Dec 2025 | −$71.9M | — |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$197.2M |
| IOVA Iovance Biotherapeutics, Inc. | −$220.5M |
| IRON Disc Medicine, Inc. compare | −$245.9M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IOVA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement